anicells, an accelerator platform for cell therapy products, aims to facilitate the go-to-patient process of cell therapy products.
Today, cell therapy is at the cutting edge of development. The use of living cells from a patient or healthy donors as a medicine has the potential to improve the lives of patients suffering from serious conditions where currently limited or no therapeutic options exist. Yet, some challenges in the development of these cell products slow down the final availability of safe, efficient and affordable treatments for all patients.
To facilitate the early clinical trials and to overcome the challenges observed in the go-to-patient process, anicells is created from a joint initiative of the University of Antwerp, the University Hospital Antwerp and POM, supported by both the Flemish and the European governments. anicells offers support services for clinical cell therapy development and access to GMP-compliant infrastructure for manufacturing cell therapy products.